HL
Helen Louise Collins sold $252K of ELVN stock
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares of ELVN stock worth $252K, per an SEC Form 4 filed Sep 21, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Sep 17, 2026, 4 days before it was made public.
ELVN has moved -5.2% since the trade date, from $50.24 to $47.62 (Nov 16, 2026 close).
- Traded
- Sep 17, 2026
- Disclosed
- Sep 21, 2026
- Filing delay
- 4 days
- Price since
- -5.2%
- Role
- Chief Medical Officer
- Source
- SEC Form 4